Cumberland's injection meets study goal

Cumberland Pharmaceuticals--which pulled off an IPO over the summer--unveiled positive results from a study evaluating the safety and efficacy of Caldolor (ibuprofen) injection in treating fever in hospitalized burn patients. The drug was given to 61 adult patients with second or third degree burns covering more than 10 percent total body surface area. Caldolor hit its primary endpoint of reducing fever in burn patients over the first 24 hours of treatment, and no safety issues were observed. The drug was administered every six hours over a five day period.

"Hospitalized burn patients often suffer from both fever and pain and our review of this data, along with results from our previous clinical work, supports our belief that Caldolor can be extremely helpful in treating these patients," said A.J. Kazimi, Cumberland's CEO. "Further, we are thrilled to reaffirm that Caldolor can be administered to hospitalized patients for five consecutive days with no safety issues."

- here's Cumberland's release
- read the Reuters release for more

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.